Clinical effectiveness of topical indigo naturalis in psoriasis

Treatment with indigo naturalis successfully targets the IL-17 signal path, similar to other systemic therapies that are much more expensive and recover a significant risk of damage.

The gene expression showed that the 15 most important signal paths included the IL-17 signal path and that it was regulated in psoriasis lesions and then regulated indigo naturalis treatment. The interleukin-17a stimulation of cultivated human keratinocytes led to a 4.5-time increase of IL-6 and a 5.5-time increase of IL-8; The IL-17A stimulation was not influenced by the presence of Isatin and indirubine, but tryptanthrin showed a significant inhibition of IL-6 and a moderate reduction in IL-8 at the highest tested concentration. Trypanthrin showed an influence on the life capacity of the cells in any of the tested concentrations.

The disease signatures of the Taiwanese study population were compared to those of a predominantly Caucasian population and it was found that they largely overlap.

practice implications

It was found that the characteristic scaly plaques of psoriasis and the increased values ​​of T-helper cells (TH) 1 and TH17 in psoriatic lesions benefit from the neutralization of the tumor necrosis factor alpha (TNF-alpha), IL-12/23 and IL-. 17a. It was thus determined that TH1/Th17 cells underpin the pathogenesis of psoriasis. ^{1.2 Traditional treatments for psoriasis, although palliative, do not respond to the role of TH1/Th17. Recent biological therapies are more effective, but costly and mount considerable risks of side effects.}

Studies by Lin et al. Previously showed the effectiveness of topical application indigo naturalis ointment in the treatment of psoriasis. 3 indigo naturalis is a traditional Chinese medicine, known as Qing Dai, and consists of a dried pigment that is obtained from a series of plants, including Baphicacanthus Cusia . This study is the first randomized, double-blind, placebo-controlled clinical study that is evaluated indigo naturalis ointment as monotherapy for moderate plaque psoriasis in a Taiwanese population. It is a joint venture of a group of investigators and Janssen Research and Development, LLC, a subsidiary of Johnson & Johnson. Despite the fact that the researchers were Janssen and had 6 Johnson & Johnson shares, this was a very well -designed, thorough study.

The researchers published new findings on the profile of molecular changes in connection with moderate plaque psoriasis. They also found this treatment with indigo naturalis successfully aims at the IL-17 signal path, similar to other systemic therapies that are much more expensive and recover a considerable risk of damage. The discovery that Typtanthin has IL-17 activity, and that the disease signatures of Taiwanese psoriasis patients largely overlap with those of Caucasians, this is close to indigo naturalis should also be effective when population of people with psoriasis.

The authors state that the short duration of the benefit is topical indigo naturalis The treatment could be due to the lack of deeper penetration in the skin and a lower systemic absorption or a short half -life of the active ingredients. Although these suggestions could be true, it may not be so current indigo naturalis of the chronic inflammatory systemic nature of psoriasis and that other approaches, including lifestyle factors, must also be effectively addressed in order to subsequently go down the phenotypical expression of the underlying genetic susceptibility to psoriasis.

Disclosure of the author: I advise Kamedis, LTD, a skin care company that has developed and marketed topical psoriasis formulation on an indigobasis.